IQOS is the only tobacco heating system to be recognised as a modified-risk tobacco product by the US Food and Drug Administration (FDA), which is responsible for protecting public health and has very strict requirements for product safety. The FDA has stated that a complete transition from regular cigarettes to IQOS reduces the body’s exposure to harmful, or potentially harmful, substances.*
After analysing the IQOS research results, the US Food and Drug Administration concluded that:
— IQOS heats tobacco without burning it.
— Eliminating the burning process significantly reduces the emission of harmful, or potentially harmful, chemicals.
— Scientific research shows that after a complete transition from regular cigarettes to IQOS, the potentially harmful substances have significantly less impact on the human body**.
This decision by the FDA shows that IQOS is a completely different product than cigarettes, and offers a better choice for adult smokers who do not intend to quit smoking.
This federal agency is responsible for protecting public health in the United States. The organisation plays an important role in assessing the safety and efficacy of drugs, biological and cosmetic products, as well as medical devices. In order to protect public health and reduce smoking in young people, the FDA is responsible for regulating the production and marketing of tobacco products, and is one of the few agencies in the world to have a special procedure for evaluating modified-risk products.
More news is coming soon.
* PMI three-month lower-impact research conducted in Japan and the United States, in conditions that are extremely close to real-life situations. The studies measured the effects of 15 selected chemicals on the selected biomarkers, and compared how these markers changed in people who switched to IQOS compared to those who continued to smoke cigarettes throughout the study.
** On 7 July 2020, the FDA issued guidance on the marketing and consumer information about IQOS as a modified-risk product.